Download
s40265-020-01445-2.pdf 811,14KB
WeightNameValue
1000 Titel
  • Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
1000 Autor/in
  1. Kauffmann-Guerrero, Diego |
  2. Kahnert, Kathrin |
  3. Huber, Rudolf M. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-11-23
1000 Erschienen in
1000 Quellenangabe
  • 81(1):87-100
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40265-020-01445-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154809/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is the leading cause of cancer-related deaths. Most NSCLC patients are diagnosed with advanced disease and require systemic treatment. Despite emerging advances in chemotherapy and immunotherapy, the prognosis of stage IV patients remains poor. However, the discovery of oncogenic driver mutations including mutations in the epidermal growth factor receptor (EGFR), the anaplastic lymphoma kinase (ALK) and others, characterize a subset of patients with the opportunity of targeted therapies. Fusions between the ALK and echinoderm microtubule-associated protein-like 4 (EML4) are present in ∼ 3-5% of patients with NSCLC. Several first-, second-, and third-generation ALK tyrosine kinase inhibitors (TKIs) have been developed in the last decade and have tremendously changed treatment options and outcomes of ALK-positive NSCLC patients. With increasing treatment options, treatment sequence decisions have become more and more complex. ALK-mutations, fusion variants, or activation of by-pass pathways result in treatment resistance during the course of treatment in nearly all patients. Mutation-guided treatment sequencing can lead to better outcomes, and re-biopsy or liquid-biopsy should be performed whenever possible in case of disease progression in ALK-rearranged patients. In the future, combinational treatment of ALK TKIs with other pathway-inhibitors might further improve patients' treatment options and outcomes. Here, we review the data for currently available ALK TKIs, discuss approaches of treatment sequencing, and give an outlook on emerging developments.
1000 Sacherschließung
lokal Carcinoma, Non-Small-Cell Lung/metabolism [MeSH]
lokal Pharmacology/Toxicology
lokal Anaplastic Lymphoma Kinase/antagonists
lokal Protein Kinase Inhibitors/pharmacology [MeSH]
lokal Anaplastic Lymphoma Kinase/metabolism [MeSH]
lokal Humans [MeSH]
lokal Review Article
lokal Antineoplastic Agents/pharmacology [MeSH]
lokal Protein Kinase Inhibitors/chemistry [MeSH]
lokal Lung Neoplasms/metabolism [MeSH]
lokal Carcinoma, Non-Small-Cell Lung/drug therapy [MeSH]
lokal Lung Neoplasms/drug therapy [MeSH]
lokal Internal Medicine
lokal Antineoplastic Agents/chemistry [MeSH]
lokal Pharmacotherapy
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2F1ZmZtYW5uLUd1ZXJyZXJvLCBEaWVnbw==|https://frl.publisso.de/adhoc/uri/S2FobmVydCwgS2F0aHJpbg==|https://orcid.org/0000-0001-7041-6368
1000 Hinweis
  • DeepGreen-ID: 975ef74c14ef4bfbbd6db9283a8431ad ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465105.rdf
1000 Erstellt am 2023-11-16T10:04:53.055+0100
1000 Erstellt von 322
1000 beschreibt frl:6465105
1000 Zuletzt bearbeitet 2023-12-01T01:37:19.692+0100
1000 Objekt bearb. Fri Dec 01 01:37:19 CET 2023
1000 Vgl. frl:6465105
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465105 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source